Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Zelluna Immunotherapy AS

Zelluna Immunotherapy specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need. The company is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long-term surviving patients from cancer vaccine trials. The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types. Zelluna, in addition to internal competences, has a long-term agreement with the Department for Cell Therapy at Oslo University Hospital, providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation. *


Period Start 2016-01-01 established
Products Industry immunotherapy
  Industry 2 TCR engineering technology (T-cell receptor engineering technology)
Persons Person Forte, Miguel (Zelluna 201711– CEO before Bone Therapeutics + TxCell + UCB + Nabi + BMS + EMA)
  Person 2 Melen, Geir Christian (Zelluna 201810– CFO before Ostomycure + Clavis Pharma + Algeta + Photocure)
Region Region Oslo
  Country Norway
  Street 64 Ullernchausséen
Oslo Cancer Cluster, Innovation Park
  City 0379 Oslo
    Address record changed: 2018-08-30
Basic data Employees n. a.
    * Document for �About Section�: Zelluna Immunotherapy AS. (10/24/18). "Press Release: Zelluna Immunotherapy Appoints Geir Christian Melen as Chief Financial Officer". Oslo.
Record changed: 2019-11-21


Picture [LSA] – The Business Web Portal 650x89px

More documents for Zelluna Immunotherapy AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top